Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vir Biotechnology, Inc.    VIR

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in August

share with twitter share with LinkedIn share with facebook
08/11/2020 | 05:05pm EDT

Aug 11 (Reuters) - Vir Biotechnology Inc said on Tuesday it plans to start a mid-to-late stage trial of its COVID-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus.

The company's therapy candidate, VIR-7831, is a monoclonal antibody that binds itself to the SARS-CoV-2 live virus and neutralizes it.

Vir Biotech expects initial clinical data from the study to be available before the end of 2020.

There are currently no approved treatments or vaccine for COVID-19, which has infected more than 20 million and killed at least 736,577, according to a Reuters tally.

Gilead Sciences Inc on Monday filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug.

Vir Biotech has two other COVID-19 antibody candidates in development, VIR-2703 and VIR-7832, and expects to start human clinical trials for both later this year.

The company received a $250 million investment from British drugmaker GlaxoSmithKline Plc in March as part of a collaboration to develop antibody treatments for COVID-19. (Reporting By Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -0.62% 62.785 Delayed Quote.-2.75%
GLAXOSMITHKLINE PLC -0.52% 1443.8 Delayed Quote.-18.38%
VIR BIOTECHNOLOGY, INC. -0.47% 34.1597 Delayed Quote.173.00%
share with twitter share with LinkedIn share with facebook
All news about VIR BIOTECHNOLOGY, INC.
09/24VIR BIOTECHNOLOGY : Publishes New Research Characterizing Antibody Response to S..
AQ
09/24Vir Biotechnology Publishes New Research Characterizing Antibody Response to ..
GL
09/16VIR BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
09/14Regeneron's antibody drug added to UK Recovery trial of COVID treatments
RE
09/14Regeneron's antibody drug added to UK Recovery trial of COVID treatments
RE
09/09VIR BIOTECHNOLOGY : to Present at Cantor Global Virtual Healthcare Conference
AQ
09/09Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference
GL
09/08VIR BIOTECHNOLOGY : to Present at H.C. Wainwright 22nd Annual Global Investment ..
AQ
09/08Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment..
GL
09/03VIR BIOTECHNOLOGY : and GSK start phase 2/3 study of COVID-19 antibody treatment
AQ
More news
Financials (USD)
Sales 2020 119 M - -
Net income 2020 -256 M - -
Net cash 2020 249 M - -
P/E ratio 2020 -16,0x
Yield 2020 -
Capitalization 4 362 M 4 362 M -
EV / Sales 2020 34,6x
EV / Sales 2021 32,5x
Nbr of Employees 253
Free-Float 85,8%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 51,67 $
Last Close Price 34,33 $
Spread / Highest target 133%
Spread / Average Target 50,5%
Spread / Lowest Target -30,1%
EPS Revisions
Managers
NameTitle
George A. Scangos President, Chief Executive Officer & Director
Vicki L. Sato Non-Executive Chairman
Howard Horn CFO, Secretary & Principal Accounting Officer
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VIR BIOTECHNOLOGY, INC.173.00%4 362
LONZA GROUP AG60.99%46 048
SEATTLE GENETICS, INC.71.27%34 049
IQVIA HOLDINGS INC.2.02%30 150
CELLTRION, INC.42.27%29 576
MODERNA, INC.261.71%27 917